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Introduction
The plakins are a class of giant cytolinker proteins that can link 
transmembrane protein complexes to the actin, intermediate fila­
ment, and microtubule (MT) cytoskeletons in various combi­
nations (Fuchs and Karakesisoglou, 2001). Plakins can bind 
actin filaments via tandem calponin homology (CH) domains, 
intermediate filaments via plakin repeat domains, and MTs 
through either a Gas2­related domain or a glycine/serine/ 
arginine domain (for review see Leung et al., 2002). The ability 
to cross­link multiple components of the cellular cytoskeleton   
allows cytolinkers to stabilize cells from mechanically induced 
damage.  Mouse  knockout  studies  exemplify  the  stabilizing   
effects of cytolinkers, as loss of the cytolinker plectin resulted 
in skin blistering and a form of muscular dystrophy (Andra   
et al., 1997), and ablation of BPAG­1, another cytolinker, caused 
skin blistering upon mechanical stimulation (Guo et al., 1995).
Dystrophin, the protein absent in patients with Duchenne 
muscular dystrophy (Hoffman et al., 1987), shows structural and 
functional similarities to cytolinkers, which suggests the hypoth­
esis that dystrophin performs a cytolinker role in muscle. Dystro­
phin’s large molecular mass of 427 kD, spectrinlike repeats, and 
ability to bind actin filaments via a tandem CH domain (Way   
et al., 1992) highlight three similarities with cytolinkers. Although 
dystrophin lacks a plakin repeat domain, dystrophin–intermediate 
filament interactions have been documented (Stone et al., 2005; 
Bhosle et al., 2006). Thus, the ability to link the actin and inter­
mediate  filament  cytoskeletons  to  the  transmembrane  dystro­
glycan complex (Suzuki et al., 1992) illustrates how dystrophin 
functions similarly to other cytolinkers. Finally, the muscle 
membrane fragility associated with the loss of dystrophin (Petrof 
et al., 1993) parallels the structural deficiencies observed in other 
cytolinker­deficient tissues, further demonstrating a close rela­
tionship between dystrophin and other cytolinkers. Collectively, 
these data support the hypothesis that dystrophin may function 
as a cytolinker in skeletal muscle.
Although dystrophin exhibits many characteristics of a 
cytolinker, a direct dystrophin–MT interaction has not been doc­
umented. Dystrophin lacks either a Gas2­related or a glycine/
serine/arginine domain, but recent studies indicated that dystro­
phin at least indirectly influences MT organization or stability 
(Percival et al., 2007; Ayalon et al., 2008). For instance, the   
dystrophin­deficient mdx mouse exhibited MT disorganization 
in skeletal muscle with the costameric MTs most severely affected 
(Percival et al., 2007). Dystrophin’s enrichment at costameres 
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and the restoration of costameric MT organization through   
virally mediated expression of a microdystrophin (Percival et al., 
2007) indicates that dystrophin is necessary for proper costameric 
MT organization in skeletal muscle. Moreover, acute knockdown 
of ankyrin­B, a protein necessary for delivery of dystrophin to the 
sarcolemma and neuromuscular junction, caused the loss of costa­
meric MTs and aberrant MT organization in a subset of MTs   
underlying the neuromuscular junction (Ayalon et al., 2008).
In this study, we investigated the hypothesis that dystro­
phin directly interacts with costameric MTs. We confirmed that 
costameric MTs were disrupted in dystrophin­deficient skeletal 
muscle and showed endogenous dystrophin cosedimented with 
MTs in tissue homogenates. Using purified proteins, we found 
that the carboxyl­terminal two thirds of dystrophin bound MTs 
with a Kd of 0.66 µM and stabilized MTs from cold­induced de­
polymerization. Finally, we documented a 2.5­fold increased 
expression of ­ and ­tubulin without alteration in the tubulin–
MT equilibrium in mdx skeletal muscle. These results demon­
strate that dystrophin is a MT­associated protein (MAP) that 
stabilizes costameric MTs and functions as a costameric cyto­
linker in skeletal muscle.
Results and discussion
To determine whether dystrophin and MTs localize to similar 
structures in skeletal muscle, we conducted immunofluorescence 
analysis on teased extensor digitorum longus muscle fibers co­
labeled with antidystrophin and anti–­tubulin antibodies (Fig. 1, 
A and B). Dystrophin forms a subsarcolemmal network with 
transverse components along the I bands and the M line and with 
longitudinal components (Williams and Bloch, 1999), whereas 
MTs form a subsarcolemmal lattice, which in fast fibers, has 
transverse and longitudinal components plus an accumulation of 
MTs around myonuclei (Ralston et al., 1999). We found that the 
transverse MTs (Fig. 1 A, arrowheads) weave their course along 
the I band dystrophin staining for long distances. MTs were also 
associated with longitudinal lines of dystrophin (Fig. 1 A, ar­
rows). These data identify domains of the subsarcolemmal cyto­
skeleton where dystrophin and MTs may interact either directly 
or  indirectly.  Next,  we  examined  MT  organization  in  mouse 
models lacking dystrophin (mdx), dystrophin’s autosomal homo­
logue utrophin (utrn
/), or both dystrophin and utrophin   
(mdx/utrn
/). Consistent with previous results (Percival et al., 
2007), loss of dystrophin resulted in MT disorganization with the 
costameric MTs appearing to be most severely affected (Fig. 1 C) 
when compared with wild type (wt; Fig. 1 C). Ablation of utro­
phin had no effect on MT organization (Fig. 1 C), which is likely 
a result of its very low expression (Rybakova et al., 2002) and 
restriction  to  the  neuromuscular  junction  (Ohlendieck  et  al., 
1991). Finally, mdx/utrn
/ skeletal muscle exhibited MT dis­
organization comparable with that of mdx (Fig. 1 C). MT organi­
zation in 24­d­old prenecrotic mdx skeletal muscle fibers was also 
disorganized, whereas age­matched wt mice displayed a MT lat­
tice nearly identical to mature wt mice (Fig. 1 D). Collectively, 
these results confirm a role for dystrophin in the stabilization and 
proper organization of costameric MTs independent of muscle 
necrosis and regeneration.
Figure 1.  Dystrophin guides MTs at the surface of the muscle fibers and is 
necessary for proper MT organization. (A) Isolated muscle fibers from the 
extensor digitorum longus of 7-wk-old wt mice were costained for dystro-
phin (left) and -tubulin (middle). The right panel shows that MTs (red) follow 
dystrophin (green) bands for long distances both transversely (arrowheads) 
and longitudinally (arrows). (B) At a higher magnification, dystrophin stain-
ing is granular; MTs are studded with dystrophin “dots.” Arrows indicate 
longitudinal MTs that follow dystrophin. (C) Muscle fibers from the extensor 
digitorum longus of 7-wk-old wt, mdx, utrn
/, and mdx/utrn
/ mice were 
stained with DM1A anti–-tubulin and Hoechst dye. Both wt and utrn
/ 
fibers show the lattice of transverse and longitudinal MTs characteristic of 
fast fibers (arrowheads). In mdx and mdx/utrn
/ fibers, the regularity of 
the lattice is lost, and mostly oblique MTs originate from cytoplasmic nucle-
ation points (arrows). (D) Peripherally nucleated prenecrotic muscle fibers 
from 24-d-old mdx mice also displayed MT disorganization, indicating that 
MT derangement occurred before muscle cell necrosis and regeneration. 
Bars: (A and B) 10 µm; (C and D) 20 µm.365 DYSTROPHIN BINDS MICROTUBULES • Prins et al.
rod domain absent from Dp260. A small amount of Dp260 pel­
leted in the absence of MTs, but substantially more Dp260 shifted 
to the pellet fraction when MTs were present (Fig. 3 A). After sub­
tracting self­pelleting Dp260, Dp260 displayed a concentration­
dependent and saturable cosedimentation with a Dp260/­ 
tubulin heterodimer stoichiometry of 1:1.4 and a Kd of 0.66 µM 
(Fig. 3 C). As predicted, DysNTerm­R10 did not cosediment with 
MTs up to concentrations approaching 10 µM (Fig. 3, B and C). 
Next, we assessed how the presence of 1 µM Dp260 affected 
the tubulin–MT equilibrium in vitro. Dp260 had no significant 
effect on the fraction of tubulin in the MT fraction when incu­
bated at room temperature (67.3 ± 0.72% vs. 68.6 ± 1.3%). 
However, the presence of Dp260 significantly increased the 
fraction of tubulin retained in the MT pellet (33.6 ± 2.9% vs. 
42.2 ± 2.0%) when MTs were induced to depolymerize by incu­
bating at 4°C. (Fig. 3, D and E). Collectively, these results dem­
onstrate that dystrophin directly binds and stabilizes MTs from 
cold­induced depolymerization.
Because misregulation of other MAPs can alter tubulin 
expression and MT stability (Harada et al., 1994; Takahashi   
et al., 2003), we investigated how the loss of dystrophin affects 
the regulation of tubulin expression and the tubulin–MT equi­
librium in skeletal muscle fibers. Tubulin levels in wt and mdx 
skeletal muscle extracts were examined by quantitative West­
ern blot analysis. With mAb B512, we observed no difference 
Next, we performed a tissue­based MT cosedimentation 
assay (Fig. 2 A) to determine whether dystrophin cosedimented 
with MTs. Under conditions that induced MT depolymeriza­
tion, virtually no muscle protein pelleted (Fig. 2 B). However, 
numerous proteins pelleted under MT­stabilizing conditions, 
and this fraction of proteins represents MTs and the MAPs of 
skeletal muscle (Fig. 2 B). We Western blotted each fraction 
obtained from the tissue cosedimentation assay performed on 
wt mice expressing full­length dystrophin or transgenic mdx 
mice expressing Dp260, microdystrophin (R4­23), or Dp71 
(Fig. 2 C, right). Full­length dystrophin, Dp260, and R4­23 
all pelleted with MTs, whereas Dp 71 did not (Fig. 2 C, left). 
By comparing the dystrophin domains present or absent in each 
construct (Fig. 2 C, right) along with each construct’s ability   
to cosediment with MTs, we suggest that spectrinlike repeat   
24 through the first third of the WW domain encodes a novel 
MT­binding domain.
To test for a direct interaction between dystrophin and MTs, 
we performed MT cosedimentation using two purified recombi­
nant dystrophin constructs and purified tubulin. The two recombi­
nant constructs used were Dp260, which encodes from spectrinlike 
repeat 10 through the carboxy terminus of dystrophin, including 
the proposed MT­binding domain, and DysNTerm­R10 (Rybakova   
et al., 2006), which encodes the amino­terminal, tandem CH   
actin­binding domain and spectrinlike repeats 1–10 of the middle 
Figure 2.  Dystrophin cosediments with MTs   
in skeletal muscle extracts. (A) Flowchart of   
tissue MT cosedimentation assay. (B) Coomassie 
blue–stained SDS-PAGE showing supernatant 
(S) and pellet (P) fractions in conditions that 
favored MT depolymerization or polymeriza-
tion. The pellet fraction in the presence of MTs 
represents the MAP fraction of skeletal muscle.   
The molecular mass standards (given in kilo-
daltons) are indicated on the left. (C, left) 
Western  blot  analysis  of  tissue  cosedimenta-
tion assay from skeletal muscle extracts of   
wt  mice  expressing  dystrophin  or  mdx  mice 
transgenically expressing Dp260, R4-R23, and 
Dp71.  (right)  Diagrammatic  representation 
of constructs analyzed in tissue cosedimenta-
tion.  ABD,  actin-binding  domain;  H,  hinge 
region;  W,  WW  domain;  CR,  cysteine-rich 
domain; CT, carboxy-terminal domain; MT BD, 
MT-binding domain.JCB • VOLUME 186 • NUMBER 3 • 2009   366
in ­tubulin expression in mdx skeletal muscle (Fig. 4, A and B). 
Because levels of ­ and ­tubulin are coregulated (Gonzalez­
Garay and Cabral, 1995), we investigated ­tubulin levels to 
determine whether ­tubulin is up­regulated in mdx skeletal 
muscle.  ­Tubulin  expression  was  elevated  2.5­fold  in  mdx 
skeletal muscle (Fig. 4, A and B), suggesting that expression of 
both  ­  and  ­tubulin  is  increased  in  mdx  skeletal  muscle. 
Thus, we conclude that mAb DM1A is able to recognize a pop­
ulation of ­tubulin not detected by mAb B512. To examine 
MT stability in mdx skeletal muscle, we analyzed levels of   
tyrosinated ­tubulin, a marker of dynamic MTs (Gundersen   
et al., 1984, 1987), and acetylated ­tubulin, a marker of long­
lived MTs (Bulinski and Gundersen, 1991). The levels of tyro­
sinated ­tubulin were increased 2.5­fold in mdx extracts   
(Fig. 4, A and B), whereas the levels of acetylated ­tubulin 
were not (Fig. 4, A and B). The loss of dystrophin’s MT­stabilizing 
ability may explain why acetylated ­tubulin was not more 
abundant in mdx skeletal muscle extracts, but alterations in the 
tubulin–MT equilibrium could also explain the lack of more 
stable MTs. Therefore, we examined the tubulin–MT equilib­
rium in wt and mdx skeletal muscles and found that the loss of 
dystrophin did not affect the equilibrium (Fig. 4, C and D). 
Collectively, these results show that tubulins are misregulated 
in dystrophin­deficient skeletal muscle without affecting the 
tubulin–MT equilibrium. The loss of dystrophin’s MT­stabilizing 
ability likely explains why there are not more stabilized MTs even 
in the presence of more tubulin dimer in dystrophin­deficient 
skeletal muscle.
An indirect link between dystrophin and MTs mediated 
by ankyrin­B was recently shown to be important for proper 
trafficking of dystrophin and ­dystroglycan to the sarcolemma 
(Ayalon et al., 2008). However, costameric MTs are disorga­
nized in mdx skeletal muscle even in the presence of properly 
localized ankyrin­B (Ayalon et al., 2008). Because the MT­ and 
ankyrin­B–binding domains of dystrophin do not overlap (Fig. 5), 
our results and previous results suggest that dystrophin interacts 
with MTs in vivo through two distinct mechanisms. We propose 
that ankyrin­B delivers dystrophin to the sarcolemma depen­
dent on MTs and that dystrophin and ankyrin­B collaborate to 
stabilize and organize MTs in skeletal muscle.
As with other cytolinkers, the ability to bind multiple com­
ponents of the filamentous cytoskeleton likely allows dystrophin 
to protect the sarcolemma from mechanically induced damage. 
One highly truncated microdystrophin construct (R4­23) is 
very effective in restoring function in the dystrophin­deficient 
mdx mouse (Harper et al., 2002). Interestingly, the R4­23 micro­
dystrophin contains all sequences required for interaction with 
the three cytoskeletal filament systems: the amino­terminal tan­
dem CH domain, which binds actin (Way et al., 1992) and cyto­
keratin filaments (Stone et al., 2005), the spectrinlike repeat   
3 and the cysteine­rich regions, which are necessary for synemin 
intermediate filament binding (Bhosle et al., 2006), and the   
MT­binding domain. In contrast, Dp260 lacks the cytokeratin 
filament–binding domain and portions of the synemin­ and actin­
binding domains, which likely alters the binding affinities to both 
actin and synemin filaments and may explain why transgenic 
overexpression of Dp260 only partially alleviates the mdx  
in ­tubulin expression between wt and mdx skeletal muscle   
extracts (Fig. 4, A and B), which was consistent with what we 
(Prins et al., 2008) and others (Barton et al., 2002) reported 
previously. However, mAb DM1A showed an 2.5­fold increase 
Figure 3.  Dp260 binds and stabilizes MTs in vitro. (A) Coomassie blue–
stained SDS-PAGE showing the supernatant (S) and pellet (P) fractions of 
purified Dp260 in the presence and absence of MTs. Dp260 shifted to the 
pellet fraction when MTs were present, indicating that Dp260 binds MTs. 
(B) Coomassie blue–stained SDS-PAGE showing the supernatant and pellet 
fractions of DysN-R10 in the presence and absence of MTs. The presence 
of MTs did not cause a shift of DysN-R10 into the pellet fraction, indicating 
that DysN-R10 does not bind MTs. (C) Concentration-dependent binding 
of Dp260 to taxol-stabilized MTs (2 µM tubulin) from three independent 
experiments.  DysN-R10  did  not  show  significant  MT-binding  activity.   
(D) Coomassie blue–stained SDS-PAGE of the supernatant and pellet frac-
tions of MTs induced to depolymerize by incubating at 4°C in the presence 
or absence of 1 µM Dp260. (E) Quantification of tubulin in the MT fraction 
when induced to depolymerize by incubating at 4°C (n = 6). The presence 
of 1 µM Dp260 significantly (t test; *, P ≤ 0.05) increased the amount of 
tubulin in the MT fraction, indicating that Dp260 stabilizes MTs. Error bars 
represent mean ± SEM. (A, B, and D) Molecular mass standards (given in 
kilodaltons) are indicated on the left.367 DYSTROPHIN BINDS MICROTUBULES • Prins et al.
pathophysiology. For example, disorganized MTs are also asso­
ciated with Golgi mislocalization (Percival et al., 2007), which 
in combination, would likely lead to impaired trafficking of 
membrane­bound proteins and may explain the decreased levels 
of ­dystroglycan and the sarcoglycans at the sarcolemma of mdx 
skeletal muscle (Ohlendieck and Campbell, 1991). Because no 
MT knockout mouse has been generated, the exact function of 
MTs in skeletal muscle remains unknown. However, the impor­
tance of MTs in skeletal muscle biology is illustrated by the muscle 
weakness and increased levels of serum creatine kinase associ­
ated with colchicine toxicity in human patients (Boomershine, 
2002; Caglar et al., 2003; Wilbur and Makowsky, 2004; Altman 
et al., 2007). Therefore, it is possible that derangement of the 
MT cytoskeleton contributes to some of the phenotypes associ­
ated with dystrophin deficiency.
Materials and methods
Mice
Control C57BL/6 and mdx mice were initially obtained from The Jackson 
Laboratory. The utrn
/ and mdx/utrn
/ mice were provided by D. Lowe 
(University of Minnesota, Minneapolis, MN). Mdx mice transgenically ex-
pressing Dp260 and R4-R23 were provided by J. Chamberlain (Univer-
sity of Washington, Seattle, WA), and the Dp71 line was provided by   
J. Rafael-Fortney (Ohio State University, Columbus, OH). All animals were 
housed and treated following guidelines set by the University of Minnesota 
Institutional Animal Care and Use Committee.
Antibodies
The mAbs to -tubulin (B512), -tubulin (D66), tyrosinated tubulin (TUB 1-A2), 
and acetylated tubulin (6-11B-1) were purchased from Sigma-Aldrich. The mAb 
to -tubulin (DM1A) was purchased from Abcam. The mAb to dystrophin (Dys2) 
was purchased from Novacastra. The polyclonal antibody to dystrophin (Rb2) 
was described previously (Rybakova et al., 1996). Infrared dye–conjugated 
anti–mouse secondary antibodies were purchased from LI-COR Biosciences.
phenotype (Warner et al., 2002). Because Dp116 harbors only the 
MT­binding domain and one of two synemin­binding sequences, 
an inability to bind cytokeratin filaments and actin filaments likely 
explains why transgenic overexpression of Dp116 fails to rescue 
the mdx phenotype (Judge et al., 2006). Finally, the mild muscle 
phenotypes of cyto­actin (Sonnemann et al., 2006) or keratin 19 
knockout mice (Stone et al., 2007) may be explained by dystro­
phin’s linkage with the remaining components of the cortical cyto­
skeleton. Collectively, these results support the hypothesis that 
dystrophin must bind all three components of the cellular cyto­
skeleton to function properly in skeletal muscle.
Although the dystrophin–MT interaction fits well with the 
structural/organization functions previously ascribed to dystro­
phin, the importance of MTs in trafficking of proteins, vesicles, 
organelles, and mRNAs (for review see Hirokawa and Noda, 
2008; Gennerich and Vale, 2009) also suggests how MT disrup­
tion in mdx skeletal muscle could contribute to the dystrophic 
Figure 4.  Mdx mice exhibit tubulin misregulation in the 
absence of an altered tubulin–MT equilibrium. (A) Repre-
sentative Western blots of tubulin levels in skeletal muscle 
extracts from wt and mdx mice. (B) Quantification of tubu-
lin levels from three wt and three mdx extracts. (C) Repre-
sentative Western blots of tubulin (tub) and MT fractions 
of skeletal muscle extracts from wt and mdx mice using 
mAb DM1A. (D) Quantification of tubulin–MT equilibrium 
from five wt and four mdx tibialis anterior muscles. Loss 
of dystrophin does not affect the tubulin–MT equilibrium. 
Error bars represent mean ± SEM.
Figure  5.  Diagrammatic  representation  of  MT-  and  ankyrin-B–binding 
domains of dystrophin. Numbers indicate amino acids of full-length dys-
trophin. H, hinge region; W, WW domain; CR, cysteine-rich domain;   
CT, carboxy-terminal domain; MT BD, MT-binding domain; Ank-B BD,   
ankyrin-B–binding domain.JCB • VOLUME 186 • NUMBER 3 • 2009   368
30 min at 4°C. The supernatant and pellet fractions were prepared and 
quantified as described in the previous paragraph.
Western blot analysis and quantification
Western blot analysis and quantification from three wt and three mdx skel-
etal muscle extracts were performed as described previously (Prins et al., 
2008). In brief, 25 µg of skeletal muscle extract was subjected to SDS-
PAGE and transferred to nitrocellulose membranes, which were washed/
blocked in a 5% milk solution in PBS for 1 h. The membranes were incu-
bated overnight with primary antibody at room temperature. The primary 
antibodies and dilutions used were mAb Dys2 (1:50), mAb B512 (1:250), 
mAb DM1A (1:250; Sigma-Aldrich), mAb D66 (1:100), and mAb 6-11B-1 
(1:100). Membranes were washed two times for 10 min in 5% milk solu-
tion at room temperature, incubated with infrared dye–conjugated second-
ary  antibody  (1:10,000)  for  30  min  at  room  temperature,  and  the 
membranes were washed in a 0.5% Tween solution in PBS two times for 
10 min. Western blots were imaged and quantified with an infrared imag-
ing system (Odyssey; LI-COR Biosciences). The Coomassie blue–stained 
posttransfer gel was analyzed densitometrically using UVP software and 
served as the loading control.
In vivo tubulin–MT equilibrium assay
The tibialis anterior was dissected, immediately placed in 1 ml of MT stabi-
lization  buffer  (1%  Triton  X-100,  50%  glycerol,  5%  DMSO,  10  mM 
Na2HPO4, 0.5 mM EGTA, and 0.5 mM MgSO4), and homogenized with 
10 strokes in a homogenizer. The resulting homogenate was centrifuged at 
100,000 g for 30 min at 25°C. The soluble portion (tubulin containing) 
was saved for analysis, whereas the pelleted portion (MT fraction) was re-
suspended in 1 mL of 1% SDS buffer then boiled for 10 min. The pellet 
fraction was centrifuged at 13,000 g for 10 min, and the soluble portion 
was saved for analysis. 25 µl of the tubulin and MT fraction was analyzed 
and quantified via Western blot using mAb DM1A on the infrared imaging 
system (Odyssey).
Statistical analysis
All data are presented as mean ± SEM. Comparison between groups was 
performed using a t test with significance defined as P ≤ 0.05.
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Immunofluorescence analysis
To analyze the MT lattice in dystrophic animal models, hindlegs of wt   
(3 and 8 wk), mdx (3, 5, and 8 wk), utrn
/ (8–10 wk), and mdx:utrn
/ 
(3, 5, and 8 wk) mice were skinned, cut as close as possible to the body, 
and fixed at room temperature for 2 h with 4% para-formaldehyde in phos-
phate buffer. They were stored in phosphate buffer until the extensor digito-
rum longus muscle was dissected and separated with fine forceps into 
mostly single fibers. These were transferred to a 24-well tissue culture plate 
and incubated with mouse on mouse (MOM)–blocking buffer (Vector Labo-
ratories) for 2 h at room temperature. Blocking buffer and every subse-
quent buffer for incubation or washing contained 0.04% saponin for 
permeabilization and 0.05% sodium azide. Fibers were incubated over-
night with mouse antitubulin (DM1A, 1:500; or B512, 1:4,000) in MOM 
diluent, washed three times for 20 min, and stained with 1:500 dilutions 
of Alexa Fluor 488 anti–mouse and Alexa Fluor 568 anti–rabbit secondary 
antibodies (Invitrogen) in MOM diluent for 2 h at room temperature. After 
three 20-min washes, one of which contained the nuclear stain Hoechst 
33342 (Sigma-Aldrich) at 2 µg/ml, fibers were mounted onto a glass slide 
in a drop of Vectashield (Vector Laboratories). Confocal images were cap-
tured with a 63× NA 1.4 oil immersion lens on a TCS SP5 confocal micro-
scope  (Leica)  in  the  Light  Imaging  Section  of  the  National  Institute  of 
Arthritis and Musculoskeletal and Skin Diseases. Gain and laser power set-
tings were adjusted to avoid saturation and use the whole linear range of 
fluorescence intensity. Unless specified, the parameters were adjusted for 
each new fiber imaged. The raw TIF images were transferred to a com-
puter (Macintosh G5; Apple), opened in Photoshop (CS2; Adobe), assem-
bled into montages, and adjusted for brightness when needed. The final 
illustrations give a faithful representation of the collected images.
Tissue MT cosedimentation assay
Tissue-based  cosedimentation  was  performed  as  described  previously 
(Hughes et al., 2008) with the following exception. The starting material 
was 200 mg of frozen skeletal muscle that was pulverized in a mortar and 
pestle cooled with liquid nitrogen then added to MT buffer (1% Triton X-100, 
50 mM Hepes, 50 mM KCl, 1 mM MgCl2, 1 mM EGTA, 0.75 mM benz-
amidine, 0.1 mM PMSF, 0.6 µg/ml pepstatin A, 0.5 µg/ml aprotinin, 
0.5 µg/ml leupeptin, iodoacetamide, and E64). The extracts were incu-
bated for 1 h at 4°C and centrifuged at 100,000 g for 40 min at 25°C. 1 mM 
of both GTP and DTT was added to the soluble fraction of the extract and 
incubated at 37°C for 5 min. The extract was split into two fractions, one 
that was incubated on ice for 15 min, and 20 µM taxol was added to the 
other and incubated at 37°C for 15 min. 300 µl of each fraction was lay-
ered onto a cushion buffer (MT buffer plus 40% sucrose) and centrifuged 
at 100,000 g for 30 min at 25°C. The supernatant was removed, and the 
pellet fraction was resuspended in a Laemmli sample buffer.
Protein purification
A cDNA-encoding Flag-tagged Dp260 (Warner et al., 2002) provided by 
J. Chamberlain was cloned into pFASTbac1 to generate a recombinant 
baculovirus expression vector using previously described methods (Rybakova 
et al., 2002). Dp260 and dystrophin Nterm-R10 were expressed and purified 
using the baculovirus expression system and anti-Flag M2 affinity chroma-
tography, respectively, as previously described (Rybakova et al., 2002), 
except the proteins were dialyzed into MT buffer without Triton X-100. Pro-
tein concentration was determined using A280 using Nanodrop software 
with  an  extinction  coefficient  of  272,495  M
1  cm
1  for  Dp260  and 
221,115 M
1 cm
1 for DysN-R10 as predicted by the Expert Protein Analy-
sis System proteomics server (Swiss Institute of Bioinformatics).
MT cosedimentation analysis
MT cosedimentation assay was performed as described by the manufactur-
er’s instructions (Cytoskeleton, Inc). In brief, increasing amounts of purified 
protein were added to preformed MTs then centrifuged at 100,000 g for 
30 min. The amount of free and bound protein was determined densito-
metrically from Coomassie blue–stained gels of the supernatant and pel-
leted fractions using imaging system software (UVP). The fraction of protein 
pelleting in the absence of MTs was subtracted from each data point. The 
resultant data from three independent experiments were fitted to a hyper-
bolic binding equation using nonlinear regression analysis on Prism soft-
ware (GraphPad Software, Inc.).
Cold-induced depolymerization assay
Tubulin was induced to polymerize as described by the manufacturer’s in-
structions (Cytoskeleton, Inc.) and incubated with 1 µM Dp260. The reac-
tions were incubated at 4°C for 30 min then centrifuged at 100,000 g for 369 DYSTROPHIN BINDS MICROTUBULES • Prins et al.
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